Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Blood-brain barrier breakdown in the aging human hippocampus.
Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, Toga AW, Jacobs RE, Liu CY, Amezcua L, Harrington MG, Chui HC, Law M, Zlokovic BV. Montagne A, et al. Among authors: amezcua l. Neuron. 2015 Jan 21;85(2):296-302. doi: 10.1016/j.neuron.2014.12.032. Neuron. 2015. PMID: 25611508 Free PMC article.
Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial.
Williams MJ, Okai AF, Cross AH, Monson NL, Vartanian T, Thrower BW, Reder AT, English JB, Wu GF, Bernitsas E, Yap S, Ndrio J, Pei J, Mowry EM, Magrini F, Acosta J, Amezcua L; CHIMES investigators. Williams MJ, et al. Among authors: amezcua l. Mult Scler Relat Disord. 2023 Aug;76:104794. doi: 10.1016/j.msard.2023.104794. Epub 2023 Jun 9. Mult Scler Relat Disord. 2023. PMID: 37356256 Free article. Clinical Trial.
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, Engebretson E, Gustafson T, Miller AE; DISCOMS investigators. Corboy JR, et al. Lancet Neurol. 2023 Jul;22(7):568-577. doi: 10.1016/S1474-4422(23)00154-0. Lancet Neurol. 2023. PMID: 37353277 Clinical Trial.
Ancestral risk modification for multiple sclerosis susceptibility detected across the Major Histocompatibility Complex in a multi-ethnic population.
Beecham AH, Amezcua L, Chinea A, Manrique CP, Gomez L, Martinez A, Beecham GW, Patsopoulos NA, Chitnis T, Weiner HL, De Jager PL, Burchard EG, Lund BT, Fitzgerald KC, Calabresi PA, Delgado SR, Oksenberg JR, McCauley JL. Beecham AH, et al. Among authors: amezcua l. PLoS One. 2022 Dec 22;17(12):e0279132. doi: 10.1371/journal.pone.0279132. eCollection 2022. PLoS One. 2022. PMID: 36548255 Free PMC article.
Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort.
Gholizadeh S, Exuzides A, Lewis KE, Palmer C, Waltz M, Rose JW, Jolley AM, Behne JM, Behne MK, Blaschke TF, Smith TJ, Sinnott J, Cook LJ, Yeaman MR; Guthy-Jackson Charitable Foundation CIRCLES Study Group. Gholizadeh S, et al. J Neurol. 2023 Apr;270(4):2048-2058. doi: 10.1007/s00415-022-11529-6. Epub 2022 Dec 24. J Neurol. 2023. PMID: 36565348 Free PMC article.
Epidemiologic trends of multiple sclerosis in Puerto Rico (2013-2020).
Chinea A, Ríos-Bedoya CF, Vicente I, Vega-Corteguera RJ, Martínez-Maldonado V, Carmona-Burgos DX, Rubí C, Amezcua L, Gilman CK, Díaz de la Matta PG, Rivera EP. Chinea A, et al. Among authors: amezcua l. Mult Scler Relat Disord. 2022 Dec;68:104240. doi: 10.1016/j.msard.2022.104240. Epub 2022 Oct 10. Mult Scler Relat Disord. 2022. PMID: 36544310 Free article.
78 results